IRCMS International Research Center for Medical Sciences

  • HOME
  • Publications
  • Mac-2 Binding Protein Glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-inf...
What's new

Publications

Mac-2 Binding Protein Glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-infected patients in West Africa

July 22 2022

Yusuke Shimakawa

Paper information

Title:
Mac-2 Binding Protein Glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-infected patients in West Africa

Jeanne Perpétue Vincent,1 Gibril Ndow,2,3 Shintaro Ogawa,4 Amie Ceesay,3 Ramou Njie,5,6 Bakary Sanneh,7 Ignatius Baldeh,7 Umberto D'Alessandro,3 Maimuna Mendy,8 Mark Thursz,2 Isabelle Chemin,9 Yasuhito Tanaka,4,10 Maud Lemoine,2,* Yusuke Shimakawa1,11,*

1 Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, Paris, France.

2 Division of Digestive Diseases, Department of Metabolism, Digestion & Reproduction, Imperial College London, London, UK.

3 Disease Control & Elimination, MRC Unit The Gambia at London School of Hygiene & Tropical Medicine, Fajara, The Gambia.

4 Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

5 Edward Francis Small Teaching Hospital, Banjul, The Gambia.

6 School of Medicine & Allied Health Sciences, University of The Gambia, Serekunda, The Gambia.

7 National Public Health Laboratories, Ministry of Health, The Gambia.

8 International Agency for Research on Cancer (IARC), World Health Organisation, Lyon, France.

9 INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie, Université Claude Bernard, Lyon, France.

10 Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

11 International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan.

* Equally contributed

Journal of Global Health

Highlights

  • To reduce mortality associated with hepatitis B virus (HBV) infection, timely detection of cirrhosis and early-stage hepatocellular carcinoma (HCC) is essential.
  • In low-income countries, however, HBV-infected people have limited access to liver histopathology, a reference test.
  • Recently, Asian studies have suggested the usefulness of an inexpensive serum biomarker called Mac-2 Binding Protein Glycosylation isomer (M2BPGi) in staging liver fibrosis and predicting HCC in HBV-infected patients.
  • We conducted a cross-sectional study of 339 HBV-infected patients in The Gambia (cirrhosis: n=65, HCC: n=73, non-cirrhosis non-HCC: n=201) to evaluate the association between M2BPGi and HCC and the performance o M2BPGi to diagnose cirrhosis.
  • Positive M2BPGi was significantly associated with both cirrhosis (adjusted OR: 7.8, 95% CI: 3.1-19.7) and HCC (adjusted OR: 10.1, 2.6-40.2).
  • To diagnose cirrhosis, the areas under the ROC curve (AUROC) was 0.80 in 49 patients with liver biopsy as a reference and 0.89 in 217 patients with transient elastography as a reference (Table).
  • This is the first evaluation of M2BPGi in HBV-infected African people and supported its use as an alternative to liver biopsy or transient elastography to diagnose cirrhosis in resource-limited countries.

Vincent JP. JGlobHealth.jpg